News and Press Releases
HUTCHMED Announces that TAGRISSO plus ORPATHYS demonstrated high,clinically meaningful response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
New data demonstrate efficacy for the oral treatment combination to address MET-driven resistance in EGFR-mutated lung cancer MET is a common biomarker in this setting for patients who develop resistance...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 16, 2024
£4.5 million project launched to tackle acute skills shortage in UK medicines manufacturing
Resilience, the UK’s first Medicines Manufacturing Skills Centre of Excellence, will use virtual reality to train in laboratory skills and support the NHS’ net-zero goal 16 October 2024 -- Birmingham,...
Category: Biotechnology, Other, Pharmaceutical
Posted: October 16, 2024
UK Research and Innovation Polaris House Swindon SN2 1FL
Bespak & H&T Presspart announce availability of GMP pilot line for low GWP pMDIs
Filling line is on track to supply clinical trial batches utilising climate-friendly propellants HFA-152a and HFO-1234ze 8 October 2024 – Holmes Chapel, UK, and Blackburn, UK – Bespak, a specialist...
Category: Drug Delivery
Posted: October 16, 2024
Cellular Origins, Fresenius Kabi Sign Development Agreement for Scalable Automation of Cell and Gene Therapy Manufacturing
Companies to develop integration strategies for Fresenius Kabi’s portfolio of Cell Therapy Technologies within Cellular Origins’ Constellation automation platform Initial research to focus on integration of the Cue Cell Processing...
Category: Biotechnology, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 16, 2024
Nipocalimab demonstrates sustained disease control in adolescents living with generalised myasthenia gravis in the Phase 2/3 study
First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied 15...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 15, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor
14 October 2024 -- Massachusetts, US, and Montreal, Canada -- Repare Therapeutics Inc, a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s Phase...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 14, 2024
Redx Presents Preclinical Data on RXC008, a Potential First-in-Class Therapy to Treat Fibrostenotic Crohn’s Disease, at the UEG Week
Presentation submission wins Top Abstract Prize The oral presentation, entitled “RXC008: First-in-Class Gastrointestinal-Targeted Potent Pan-ROCK Inhibitor for Treatment of Fibrostenotic Crohn’s Disease”, was delivered on Monday 14 October, during the...
Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: October 14, 2024
Block 33 Mereside, Alderley Park Alderley Edge Macclesfield SK10 4TG UK
Ingenza announces move to purpose-built facilities to expand fermentation and research capacity
1 October 2024 – Roslin, Scotland – Ingenza – a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator – is delighted to announce its plans to relocate...
Category: BioManufacturing
Posted: October 14, 2024
Ingenza Ltd, Roslin Innovation Centr,e Charnock Bradley Building, Easter Bush Campus, Bush Farm Road, Roslin, EH25 9RG, UK
3PBIOVIAN strengthens its leadership team with the appointment of a Business Development Director for Advanced Therapies
This strategic hire will further solidify 3PBIOVIAN’s position as a leading CDMO in the development of advanced therapies and enhance its international commercial team October 9, 2024 – Noáin, Spain–...
Category: BioManufacturing
Posted: October 11, 2024
CPHI Milan Report: CMOs and hybrid companies will hold 54% of biologics capacity in 2028
CMOs will account for four of the five biggest capacity holders in 2028, with 45% of all CMO capacity in Asia The world’s largest pharma event, CPHI Milan, is set...
Category: Pharmaceutical
Posted: October 11, 2024
Biotech Capital on the Rise and Outsourcing to Accelerate in 2025 – but Uneven Growth for CDMOs
European Biotech Recovery Gains Momentum as Chinese Biotech Declines, and IPO Activity Remains Weak New research launched at CPHI Milan – the world’s largest pharma event, held at Fiera Milano...
Category: Pharmaceutical
Posted: October 11, 2024
The 2024 PPMA Show is hailed a huge success
The PPMA Show, the UK’s leading event for processing and packaging machinery, including industrial automation and machine vision systems, has once again been acclaimed as a great success. Established more...
Category: Manufacturing and Packing, Pharmaceutical
Posted: October 10, 2024
3PBIOVIAN strengthens its leadership team with the appointment of a Business Development Director for Advanced Therapies
This strategic hire will further solidify 3PBIOVIAN’s position as a leading CDMO in the development of advanced therapies and enhance its international commercial team 9 October 2024 -- Noáin, Spain...
Category: Drug Delivery, Other, Pharmaceutical
Posted: October 9, 2024
WCG Releases 2024 Report on Top Issues Impacting Clinical Research Sites
8 October 2024 -- New Jersey, US -- WCG, the global leader in providing solutions that measurably improve the quality and efficiency of clinical research, today released the WCG 2024 Clinical Research...
Category: Clinical Trials, Other, Pharmaceutical
Posted: October 8, 2024
Mosaic Therapeutics appoints Dr Barry Davies as CSO
Former AstraZeneca Senior Director, Global Project Leader adds significant experience and expertise to leadership team Appointment will drive further development of Mosaic’s targeted oncology combination therapies pipeline and platform. 7...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: October 7, 2024
Mosaic Therapeutics Wellcome Genome Campus Cambridge CB10 1DR
